SEOUL, Feb. 4 (Yonhap) -- Celltrion Healthcare Co., an affiliate of one of South Korea's leading biopharmaceuticals, said Monday that it has inked a series of deals in recent months to sell its biosimilar drug Truxima in three Central and South American countries.
Truxima -- based on Rituxan, originally developed by Swiss pharmaceutical giant Roche Holding AG -- will be sold in Ecuador, Guatemala and Costa Rica, the company said.
Celltrion Healthcare handles overseas business operations for Celltrion Inc.
Truxima is used in the treatment of a number of diseases in adult patients, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukemia, the company said.
The affiliate said it has recently won a contract through a bidding that was taken in Ecuador during the fourth quarter of last year.
Celltrion said it has so far won sales approval for Truxima from a total of seven Central and South American countries, and expects to earn additional approvals in Brazil, Chile and Peru this year.
Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire.
S. Korea's space program opens new chapter with rocket engine launch, satellites
Samsung aims to overcome biz hurdles through 180 tln won investment
Naver's relinquishing of news editing first step to addressing opinion rigging concerns
(News Focus) All eyes on Samsung's stock split, impact on share value
Samsung's stock split move to make it possible for ordinary investors to buy-sell shares